Medivation Inc.'s investor call after the close of trading on July 6 proved to be an obvious attempt to encourage higher bids from a group of multiple suitors who are engaged in confidential talks to acquire the San Francisco-based cancer specialist, with one analyst saying the firm's booster efforts behind Phase III PARP inhibitor talazoparib could not have been more transparent.
Having passed on an upgraded purchase offer from Sanofi, Medivation announced on July 5 that the French pharma had dropped...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
